Table 2.
SPM risk associated with FAS and FASLG polymorphisms after index SCCH
| Genotypes | Total (No. =1,286) | SPM-free (No. =1,166) | SPM (No. =120) | Pa | HR(95% CI)b | |||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |||
| FAS -1377G>A | ||||||||
| GG (Ref.c) | 1,023 | 79.6 | 927 | 79.5 | 96 | 80.0 | ||
| GA+AA | 263 | 20.4 | 239 | 20.5 | 24 | 20.0 | 0.879 | 0.87 (0.56–1.36) |
| FAS -670A>G | ||||||||
| AA (Ref.c) | 333 | 25.9 | 313 | 26.8 | 20 | 16.7 | ||
| AG+GG | 953 | 74.1 | 853 | 73.2 | 100 | 83.3 | 0.014 | 1.57 (1.00–2.54) |
| FASLG -844C>T | ||||||||
| CC (Ref.c) | 511 | 39.7 | 476 | 40.8 | 35 | 29.2 | ||
| CT+TT | 775 | 60.3 | 690 | 59.2 | 85 | 70.8 | 0.038 | 1.71 (1.15–2.54) |
| FASLG -124A>G | ||||||||
| AA (Ref.c) | 981 | 76.3 | 889 | 76.2 | 92 | 76.7 | ||
| AG+GG | 305 | 23.7 | 277 | 23.8 | 28 | 23.3 | 0.458 | 1.15 (0.75–1.77) |
a
χ2 test for differences in the distributionof FAS and FASLG genotypes between the patients who developed SPM and the patients who did not.
b
Adjusted for age, sex, ethnicity, tobacco smoking and alcohol drinking in a Cox model.
c
Ref. = reference group.